Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • EGFR
    (4)
  • Autophagy
    (3)
  • Ferroptosis
    (3)
  • SARS-CoV
    (1)
  • Others
    (2)
Filter
Search Result
Results for "

lapatinib

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    8
    TargetMol | Inhibitors_Agonists
  • PROTAC Products
    1
    TargetMol | PROTAC
  • Isotope Products
    1
    TargetMol | Isotope_Products
Lapatinib
GW572016, GSK572016
T0078231277-92-2
Lapatinib (GW572016) is an inhibitor of ErbB2 and EGFR (IC50=9.2 10.8 nM) with oral activity. Lapatinib has antitumor activity and can be used to treat advanced or metastatic breast cancer with HER2 overexpression.
  • Inquiry Price
Size
QTY
Lapatinib ditosylate monohydrate
Lapatinib ditoluenesulfonate monohydrate, Tyverb ditosylate monohydrate, Lapatinib ditosylate monohydrate, Lapatinib ditosilate hydrate, Tykerb ditosylate monohydrate
T0078L388082-78-8
Lapatinib ditosylate (Lapatinib tosilate) monohydrate is a tyrosine kinase receptor inhibitor used in the therapy of advanced breast cancer and other solid tumors. Lapatinib ditosylate monohydrate therapy is associated with transient elevations in serum aminotransferase levels and rare instances of clinically apparent acute liver injury.
  • Inquiry Price
Size
QTY
Lapatinib Ditosylate
Tykerb ditosylate, Lapatinib (GW-572016) Ditosylate, GW-572016 ditosylate
T6235388082-77-7
Lapatinib Ditosylate (Tykerb ditosylate) is an effective EGFR and ErbB2 inhibitor (IC50: 10.8 9.2 nM for EGFR ErbB2).
  • Inquiry Price
Size
QTY
lapatinib tosylate
GW572016 tosylate ; GW2016 tosylate, GW572016 tosylate, GW2016 tosylate
T725771187538-35-7
Lapatinib tosylate (GW572016), a robust and orally administered inhibitor specifically targeting the tyrosine kinase domains of ErbB-2 and EGFR, exhibits inhibitory concentration 50 (IC50) values of 10.2 nM and 9.8 nM against purified EGFR and ErbB-2, respectively.
  • Inquiry Price
1-2 weeks
Size
QTY
Lapatinib-d4
TMIH-0294
Lapatinib-d4 is a deuterated compound of Lapatinib. Lapatinib has a CAS number of 231277-92-2. Lapatinib is a dual inhibitor of Lapatinib is a dual ErbB2 EGFR (IC50: 9.2 10.8 nM) inhibitor
  • Inquiry Price
7-10 days
Size
QTY
Sapitinib
AZD-8931
T6092848942-61-0
Sapitinib (AZD-8931) , a reversible, ATP competitive inhibitor of EGFR(IC50=4 nM), ErbB2(IC50=3 nM) and ErbB3(IC50=4 nM), is more effective over Gefitinib or Lapatinib against NSCLC cell, 100-fold more specific for the ErbB family over MNK1 and Flt.
  • Inquiry Price
Size
QTY
SARS-CoV-2-IN-110
T205095
SARS-CoV-2-IN-110 (compound Bb1) is an inhibitor of SARS-CoV-2, demonstrating antiviral efficacy with an EC50 of 1.10 μM, and significantly reduced toxicity compared to Lapatinib. The compound exhibits a CC50 of greater than 100 μM against SARS-CoV-2, with a selectivity index (SI) exceeding 91.
  • Inquiry Price
Size
QTY
SJF 1528
T362452230821-38-0
Potent EGFR Degrader (DC50 values are 39.2 nM for wild-type EGFR in OVCAR8 cells and 736 nM for Exon20Ins mutated EGFR in HeLa cells). Also degrades HER2. Comprises the EGFR inhibitor lapatinib (Cat. No. 6811) joined by a linker to a von Hippel-Lindau (VHL) recruiting ligand. Inhibits proliferation of HER2-driven breast cancer cell lines (IC50 = 102 nM for SKBr3 cells).
  • Inquiry Price
Size
QTY